All News
2025 BSR Guideline for Treatment of Axial Spondyloarthritis
The British Society of Rheumatology has published its 2025 Guidelines for the Treatment of Axial Spondyloarthritis (axSpA); addressing axial and extra-musculoskeletal manifestations including acute anterior uveitis, psoriasis and IBD.
Read Article
Senescent "Zombie" Cells and Low Back Pain
d
EurekAlert!
In a preclinical study led by McGill University researchers, two drugs targeting “zombie cells” have been shown to treat the underlying cause of chronic low back pain.
Read Article
ACR & Arthritis Foundation Denounce the Dismantling of Vital Health Programs
As organizations representing nearly 60 million adults and children living with arthritis in the United States and the rheumatologists and health care professionals who treat them, we are deeply https://t.co/VH3hPz115f
Dr. John Cush RheumNow ( View Tweet)
RA diagnosis is evolving, and so are the biomarkers behind it. Dr. @WalterMaks walks through the clinical significance of 14-3-3eta—how it detects joint damage earlier and supports personalized disease management. Sponsored by Augurex.
Learn more: https://t.co/LxW9Yy9AdU https://t.co/29x0Z2yCW8
Links:
Dr. John Cush RheumNow ( View Tweet)
Diabetes Prevention with Hydroxychloroquine in Sjogren’s
A Taiwanese insurance claims analysis looked at HCQ use in primary Sjögren syndrome (pSS) and showed that HCQ exposure significantly reduces the risk of new onset diabetes in pSS. Conversely, higher doses of https://t.co/WQD0RNfm5Z
Dr. John Cush RheumNow ( View Tweet)
Retrospective study of 334 children with non-organic amplified MSK pain syndr(AMPS) plus back pain. Pts w/ localized AMPS were more likely to have a (+) straight leg raising test (P 0.01) & diffuse AMPS more likely to have allodynia & incongruent affect (reporting pain, but still https://t.co/qqCrL7b4H2
Dr. John Cush RheumNow ( View Tweet)
Long-term response of an IL-23i in PsA
Treatment response in PsA symptom improvement, disease control, skin improvement, and pain reduction through ~4 years. Sponsored by AbbVie Medical Affairs + Health Impact. https://t.co/qq5Z4SgKv5 https://t.co/3r8WsX2Dp7
Dr. John Cush RheumNow ( View Tweet)
An emulation trial shows that Humira biosimilars (Amjevita & Imraldi) were equivalent to Humira in psoriasis & achieving PASI <=2, both for new biologic starts and for biologic switchers. https://t.co/8lTGGs2rbP https://t.co/T6rTJ5ESj2
Dr. John Cush RheumNow ( View Tweet)
CDC's Committee on Immunization (ACIP) met and recommended:
1. Expand strains for meningococcal vax
2. Lower age for RSV vax > 50y
3. Rec. chikungunya vax for certain travelers
- Flu & Covid Vax to be up next mtg 6/25 https://t.co/jInnR5JSxS https://t.co/PXg0HDLgnL https://t.co/Vro5mbjG9R
Links:
Dr. John Cush RheumNow ( View Tweet)
Just published, a review of Inflammasomopathies: mechanisms and disease signatures - these are Gain-of-function mutations in inflammasome receptors leading to chronic inflammatory conditions. https://t.co/kDebFdXlx9 https://t.co/NeJrgI9eRV
Dr. John Cush RheumNow ( View Tweet)
Bullhead Sign in #SAPHO Syndrome
▶️Synovitis,
▶️Acne
▶️Pustulosis
▶️Hyperostosis
▶️Osteitis
👉🏽https://t.co/ownI4Q543w
via @MayoProceedings https://t.co/FXlTtmsDDX
Dr Ai Lyn Tan DrAiLynTan ( View Tweet)
If you see women with inflammatory arthritis who are pregnant or planning a pregnancy, the MAMA Study may be recruiting at an obstetric unit near you.
To find out what is happening, visit @TheMAMAStudy, https://t.co/N8B5MpTsRx, or email mama@npeu.ox.ac.uk. @NPEU_CTU @NPEU_Oxford https://t.co/lQdgUiZ0Cb
BSR RheumatologyUK ( View Tweet)
✅ Management of #REFRACTORY skin manifestations in patients with #LUPUS ➡️ my practical tips 💪 for #PANLAR2025 🇲🇽 https://t.co/KnJO0eXI4W
Laurent ARNAUD Lupusreference ( View Tweet)
RHEUMATOLOGISTS: What is your initial steroid dosing regimen w/ Class III/IV Lupus nephritis?
Dr. John Cush RheumNow ( View Tweet)
RHEUMATOLOGISTS: Which regimen do you choose for Class V Lupus Nephritis
Dr. John Cush RheumNow ( View Tweet)
🔓 Unlock the latest in lupus care!
RheumNow presents Lupus Unlocked – Keys to Mastery, a month-long dive into clinical insights and expert perspectives.
KOL videos & articles
Tuesday Nite Rheumatology Webinars
Weekly Podcasts
Surveys + Downloadable Slides
📅 Launching May 1 – https://t.co/g0NP1NZe9k
Dr. John Cush RheumNow ( View Tweet)
Osteoarthritis Risky Business (4.18.2025)
Dr. Jack Cush reviews the news and Journal reports from this week on RheumNow. Osteoarthritis patients have unique risks and synovial fluid WBC numbers can tell you when to worry about septic arthritis in gout and pseudogout patients. https://t.co/T9KGoOBANN
Dr. John Cush RheumNow ( View Tweet)
2001–2015 Danish national health registry study of 1.8 million adults, including 290,781 w/ knee or hip #OA & 1.5 million age-, sex-, education-matched controls. Women w/ knee or hip OA had 44% higher risk of CV Dz (HR 1.44), while men w/ HOA/KOA lesser incr (HR 1.24) CV risk https://t.co/C3ZHZiM38T
Dr. John Cush RheumNow ( View Tweet)
Enzyme Porcupine inhibition of Wnt signaling is a promising treatment forsclerosteosis - rare Dz caused by SOST mutations & loss of functional sclerostin. Results in high bone mass & skeletal overgrowth (Sxs of facial paralysis, hearing loss, incr intracranial pressure https://t.co/Bgr5zoHyMG
Dr. John Cush RheumNow ( View Tweet)
JAMA Pt Education handout - Scleroderma https://t.co/UpK24WfyNF
Links:
Dr. John Cush RheumNow ( View Tweet)